<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27982350</article-id><article-id pub-id-type="pmc">5144560</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20160079</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Valvular Disorders in Carcinoid Heart Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Shi-Min</given-names></name><degrees>MMed, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><aff id="aff1"><label>1</label>MMed, PhD. The First Hospital of Putian, Teaching
Hospital, Fujian Medical University, Fujian Province, China</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Shi-Min Yuan, Longdejing
Street, 389 - Chengxiang District - Putian Fujian Province, People's Republic of
China. E-mail: <email>shiminyuan@126.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2016</year></pub-date><volume>31</volume><issue>5</issue><fpage>400</fpage><lpage>405</lpage><history><date date-type="received"><day>06</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><p>Carcinoid heart disease is a rare but important cause of intrinsic right heart
valve disorders leading to right heart failure. Occasionally, left-sided heart
valves may also be involved. The characteristic cardiac pathological findings of
carcinoid heart disease are endocardial thickening as a result of fibrous
deposits on the endocardium. Echocardiographic examination and right heart
catheterization are very useful for the diagnosis of the lesion. If more cardiac
valves are affected, multiple valve replacement should be considered. The
management of the pulmonary valve lesion depends on the extent of the diseased
valve, either by valvulotomy, valvectomy, or valve replacement. Percutaneous
valve implantations in the pulmonary and in the inferior vena cava positions
have been advocated for high-risk patients.</p></abstract><kwd-group><kwd>Carcinoid Heart Disease</kwd><kwd>Heart Failure</kwd><kwd>Pulmonary Valve Stenosis</kwd><kwd>Tricuspid Valve Insufficiency</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="30%" span="1"/><col width="70%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">5-HT</td><td align="left" rowspan="1" colspan="1"><bold>= 5-hydroxytryptamine</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">5-HIAA</td><td align="left" rowspan="1" colspan="1"><bold>= 5-hydroxyindoleacetic acid</bold></td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Carcinoid heart disease, also known as Hedinger syndrome, is rare affecting at least
20% of patients with carcinoid syndrome. It is considered as a result of high
circulating hormone levels, mainly serotonin, impacting on the heart, leading to
most commonly valvular fibrosis<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.
It is an important cause of intrinsic right heart valve disorders with significant
morbidity and mortality secondary to right heart failure<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Cardiac involvement in carcinoid disease generally
results in right-sided valvular lesions, accompanied by tricuspid insufficiency and
pulmonary stenosis. The typical valvular lesions of carcinoid heart disease include
both tricuspid regurgitation and pulmonary valve stenosis, and the evolving right
heart failure may lead to more prominent symptoms<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. In addition, Materazzo et al.<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup> and Le M&#x000e9;tayer et
al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> reported left-sided
cardiac involvement in carcinoid disease.</p></sec><sec><title>PATHOLOGY</title><p>Carcinoid heart disease are caused by endocardial deposition of pearly fibrotic
plaques (notable for absence of elastic fibers) that generally extend to the
right-sided valves, leading to multiple patterns of severe valve dysfunction. Plaque
formation causes annular constriction, leaflet thickening, and fusion of the
subvalvular apparatus. Marked degeneration of the leaflet architecture leads to
severe retraction and noncoaptation of the valve<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Typically, carcinoid heart disease involves the
right-sided endocardium, valves and subvalvular apparatus<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. The deposition of carcinoid plaques, fibrous
tissue, myofibroblasts and collagen results in annular constriction, leaflet
thickening and retraction, and subvalvular fusion and shortening<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. Tricuspid regurgitation was almost
universal at 92-100%, followed by tricuspid stenosis (38-44%), pulmonary
regurgitation (31-38%), and pulmonary stenosis (25-31%). The prevalence of
left-sided disease was 0-39%, and most of the advanced right-sided cardiac
abnormalities had a lower frequency of left-sided disease than did those with mild
right-sided abnormalities<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Luis
et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> defined the proportions
of the valve pathologies of carcinoid heart disease (<xref ref-type="table" rid="t1">Table 1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Relative proportions of valvular pathologies in carcinoid heart disease.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Heart valve</th><th align="center" rowspan="1" colspan="1">Most common</th><th align="center" rowspan="1" colspan="1">Less common</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tricuspid valve</td><td align="left" rowspan="1" colspan="1">Isolated regurgitation</td><td align="left" rowspan="1" colspan="1">Mixed stenosis &#x00026; regurgitation</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary valve</td><td align="left" rowspan="1" colspan="1">Mixed regurgitation &#x00026; stenosis</td><td align="left" rowspan="1" colspan="1">Isolated regurgitation, or, isolated stenosis</td></tr><tr><td align="left" rowspan="1" colspan="1">Left sided valve</td><td align="left" rowspan="1" colspan="1">Isolated regurgitation</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><p>The characteristic pathological findings are endocardial plaques of fibrous tissue
that may involve the tricuspid valve, pulmonary valve, cardiac chambers, venae
cavae, pulmonary artery, and coronary sinus. The fibrous reaction may involve not
only the valve leaflets, but also the subvalvar apparatus, including the tendinous
chords and papillary muscles of the tricuspid valve, and more rarely the mitral
valve in cases with left sided involvement. The fibrous tissue in the plaques
results in distortion of the valves leading to either stenosis, regurgitation, or
both. The preferential right heart involvement is most likely related to
inactivation of the vasoactive substances by the lungs. In the 5-10% of cases with
left-sided valvar pathology, one should suspect either extensive liver metastases,
bronchial carcinoid, or a patent foramen ovale<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Cardiac carcinoid plaques have been related to the
exposure of the right heart to serotonin and other tumor byproducts released from
hepatic metastases<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.
Ninety-seven percent of the patients with cardiac involvement had tricuspid valve
disease, of whom 90% displayed moderate or severe tricuspid regurgitation; smaller
numbers had coexistent tricuspid stenosis. Pulmonary valve pathology was noted in
88% of patients, of whom 81% had pulmonary regurgitation, 53% had pulmonary
stenosis, and only 7% had left-sided involvement, in whom the most typical feature
was mild-to-moderate mitral regurgitation<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p><p>In carcinoid heart disease, the characteristic cardiac pathological findings are
endocardial plaques of fibrous tissues<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Usually, only carcinoid tumours that invade the liver
result in pathological changes to the heart. The cardiac manifestations are caused
by the paraneoplastic effects of vasoactive substances, such as 5-hydroxytryptamine
(5-HT or serotonin), histamine, tachykinins, and prostaglandins released by the
malignant cells rather than any direct metastatic involvement of the heart.
Ordinarily, the vasoactive tumor products are inactivated by the liver, lungs, and
brain, but the presence of hepatic metastases may allow large quantities of these
substances to reach the right side of the heart without being inactivated by the
liver<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Serotonin is a
common product of carcinoid tumors and it contributes to cardiac failure as a result
of fibrous deposits on the endocardium. Most such tumors contain tryptophan
hydroxylase, which is able to produce serotonin after hydroxylation and subsequent
decarboxylation of the tryptophan. 5-Hydroxyindoleacetic acid (5-HIAA) is the main
metabolite, an oxidation product, of serotonin. In urine samples, 5-HIAA can be
detected for the determination of serotonin levels in the body. There is a
significant correlation between carcinoid heart disease and elevated urinary 5-HIAA
excretion, which is indicative of serotonin production. However, non-carcinoid heart
disease patients reported in literature have significantly lower serotonin
release<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Zuetenhorst
et al.<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup> also found that median
levels of N-terminal pro B-type natriuretic peptide and 5-HIAA were significantly
higher in patients with carcinoid heart disease compared to those without (894 ng/L
<italic>vs.</italic> 89 ng/L, <italic>P</italic>&#x0003c;0.001; 815 mmol/24 hours
<italic>vs.</italic> 206 mmol/24 hours, <italic>P</italic>=0.007), but no
significant differences were detected in atrial natriuretic peptide levels. Dilation
of the right atrium and ventricle as well as thickening of the tricuspid valve and
degree of regurgitation were statistically significant correlated with N-terminal
pro B-type natriuretic peptide levels. Patients in the progression of carcinoid
heart disease with a cardiac score increase &#x0003e;25% had a significant higher urinary
peak 5-HIAA levels than those &#x0003c;25% (265 mg/24 hours <italic>vs.</italic> 189
mg/24 hours; <italic>P</italic>=0.004)<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Patients with carcinoid syndrome therefore have raised
concentrations of 24 hour urinary 5-HIAA. In a large series of patients with
carcinoid syndrome and cardiac involvement the mean 24 hour urinary excretion of
5-HIAA was 10-fold higher than the reference value (reference value, 50 mmol/L/24
hours). Some studies suggest that a positive correlation exists between urinary
concentrations of 5-HIAA, disease progression and worsening prognosis. This has been
attributed to the fact that higher circulating concentrations of vasoactive
substances produced by the tumor (especially 5-HT causing fibroblast proliferation)
are likely to induce more cardiac damage. In patients with both right- and
left-sided carcinoid heart disease, urinary values of 5-HIAA appear to be higher in
patients without interatrial shunts compared to those with interatrial
shunts<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p></sec><sec><title>DIAGNOSIS</title><p>The characterized triad symptoms of carcinoid syndrome are cutaneous vasomotor
flushing, gastrointestinal hypermotility and cardiac involvement<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Symptoms of flushing and
diarrhea were almost threefold more common in the cardiac group. Circulating
serotonin levels were more than twofold higher in the cardiac group. Urine levels of
the serotonin metabolite 5-HIAA were almost fourfold higher in the heart disease
patients compared with the noncardiac group (219&#x000b1;124 mg/24 hours
<italic>vs.</italic> 55.3&#x000b1;141 mg/24 hours,
<italic>P</italic>&#x0003c;0.001). Elevated serum serotonin (above the upper limit of
normal range, <italic>i.e.</italic>, &#x0003e;1500 &#x000b5;mol/mL) was 100% sensitive
but only 46% specific for carcinoid heart disease<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Carcinoid tumors secrete a variety of agents,
including kallikrein, histamine, prostaglandins, adrenocorticotropic hormone,
gastrin, calcitonin, and growth hormone; however, serotonin has received the most
attention in hypotheses concerning the genesis of heart disease. Elevated urinary
5-HIAA is a less-than-ideal serotonin surrogate because it misses 10% of patients
with true elevated circulating serotonin levels<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. These symptoms are caused by the release of vasoactive
substances, mainly 5-HT as well as 5-hydroxytryptophan, histamine, bradykinin,
tachykinins, and prostaglandins<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. Tricuspid valve disease (especially regurgitation) was most
prevalent. The left-sided valve lesions tended to be less common and of milder
severity than their right-sided counterparts. Cardiac catheterization and
echocardiography had an overall concordance of 91% on the basis of valvular
lesions<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Some 92% had
New York Heart Association class III or IV symptoms of congestive heart failure, and
8% had class II symptoms. Right-sided filling pressures were mildly to moderately
elevated, whereas left-sided filling pressures were generally normal<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. In such patients, physical
examination usually reveals a systolic murmur along the left sternal edge, produced
by tricuspid regurgitation; concomitant murmurs of pulmonary stenosis or
regurgitation may also be present<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. In many patients, the structural valvular lesions will lead to
symptomatic right-sided heart failure (edema, hepatomegaly, fatigue with exertion,
and low cardiac output)<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. The
diagnosis of carcinoid syndrome is usually suspected by the clinical features and
confirmed by identification of the primary tumor, localization of metastatic
lesions, and detection of increased urinary excretion of the by-product of serotonin
metabolism, 5-HIAA<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>. Laboratory
tests may reveal an elevated <italic>&#x003b3;</italic>-glutamyl transpeptidase
due to liver metastases<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>.
Patients with carcinoid heart disease typically present with symptoms of right heart
failure (hepatomegaly, edema, ascites, fatigue and low cardiac output)<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. The diagnosis of carcinoid heart
disease can be delayed as hepatic dysfunction and may conceal the signs and symptoms
of right heart failure<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Right
ventricular enlargement and decreased right ventricular function can also be noted
on echocardiography<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>.
Echocardiographic examination and right heart catheterization are very useful in
defining the disease. Catheterization confirms severe tricuspid incompetence with a
v-wave in the right atrium and marked regurgitation evident on right ventricular
angiography<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.
Characteristic echocardiographic findings include endocardial thickening and lack of
compliance of the right ventricle, in addition to the typical thickening of both
pulmonary and tricuspid valves, with significant pulmonary stenosis and tricuspid
insufficiency<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. The
echocardiographic visualization of carcinoid heart disease is listed in <xref ref-type="table" rid="t2">Table 2</xref>.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Echocardiographic findings of carcinoid heart disease<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p></caption><table frame="hsides" rules="cols"><colgroup span="1"><col width="20%" span="1"/><col width="80%" span="1"/></colgroup><thead><tr style="border-bottom-width:thin;border-bottom-style:solid"><th align="center" rowspan="1" colspan="1">Echocardiographic technique</th><th align="center" rowspan="1" colspan="1">Echocardiographic findings</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Leaflet: thickening, retraction, reduced mobility,
laminar regurgitant flow</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Valve: incomplete coaptation</td></tr><tr><td align="left" rowspan="1" colspan="1">Two-dimensional</td><td align="left" rowspan="1" colspan="1">Right ventricular free wall: thickening Small
pericardial effusions</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Right atrium and (or) right ventricle enlargement
(81%)</td></tr><tr style="border-bottom-width:thin;border-bottom-style:solid"><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Thickened immobile tricuspid valve (56%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">"Dagger" shaped Doppler profile with early peak &#x00026;
rapid decline (severe tricuspid regurgitation)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Typical parabolic profile (less severe tricuspid
regurgitation)</td></tr><tr><td align="left" rowspan="1" colspan="1">Continuous Doppler</td><td align="left" rowspan="1" colspan="1">Increased regurgitant flow (2.6&#x000b1;0.5 m/s;
range, 1.5-4.0 m/s)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Prolonged pressure half-time (116 &#x000b1; 43 ms;
range, 45-200 ms) (tricuspid regurgitation)</td></tr><tr style="border-bottom-width:thin;border-bottom-style:solid"><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Steep pressure half-time (pulmonary regurgitation)</td></tr><tr><td align="left" rowspan="1" colspan="1">Color Doppler</td><td align="left" rowspan="1" colspan="1">Colored reverse flow</td></tr></tbody></table></table-wrap></sec><sec><title>TREATMENT</title><p>Commonly diuretic therapy and supportive therapy are essential for peripheral edema,
hepatic congestion and ascites<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.
Medical treatment include somatostatin analogs (such as, octreotide and lanreotide)
for reducing urinary 5-HIAA, cytotoxic chemotherapy for extensive disease and dual
endothelin receptor antagonist (such as, bosentan) for preventing valvular and mural
fibrosis and improving heart function<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. The somatostatin analogues act by binding to somatostatin
receptors, inhibiting secretion of tumor byproducts, and alleviating symptoms in the
majority of patients<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Relief
of symptoms can be achieved surgically by debulking the tumor, and sometimes, in
those with hepatic metastases, by hepatic artery ligation or embolization<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p><p>The surgical indications of carcinoid heart disease are, 1) symptomatic right
ventricular failure; 2) severe valvular dysfunction; 3) systemic venous pressure
elevation<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>; and 4) as a
prelude to planned surgical hepatic tumor resection<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Whereas, the contraindications are, 1) end-stage
metastatic disease, and 2) patients with poorly controlled carcinoid symptoms
despite octreotide therapy, or hepatic dearterialization<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. When the pulmonary insufficiency is mild and
very well tolerated and when the left heart filling pressures are normal, pulmonary
valve replacement is unnecessary. The optimal surgical approach to right-sided
valvular lesions remains a subject of debate. Tricuspid valve replacement has been
accepted by most centers, however, the management of pulmonary valvular disorder
remains debatable. If pulmonary valve regurgitation is left untreated, there would
be right ventricular overload in the long run; whereas in patients with pulmonary
valve replacement, the postoperative recovery appear to be more favorable<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. By comparison, the limitations for
homograft use for pulmonary valve replacement are homograft constriction, homograft
calcification, homograft plaque deposition; while the advantages of bioprosthesis
are remarkable in better short-term outcomes, longer valve durability, free of
anticoagulate uptake and uncommon carcinoid involvement<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. When the pulmonary and tricuspid valves are both
involved, open pulmonary valvulotomy is a reasonable option. If more cardiac valves
are affected, multiple valve replacement should be considered. In most cases,
involvement of the valve leaflets is too extensive to allow surgery for
commissurotomy or valvotomy, and pulmonary valvectomy surgery is required. Narine et
al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> recommend the use
of mechanical prostheses in carcinoid heart disease with a concern of the fibrous
degeneration of the bioprosthetic valves. Some reports of surgical treatment of
tricuspid insufficiency due to carcinoid disease describe use of mechanical
prostheses<sup>[<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup>, and pulmonary valve replacement
has been advocated<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. Due to the
increased risk for repeat surgical valve replacement, percutaneous stent
implantation into the pulmonary artery, followed by the implantation of a balloon
expandable transcatheter heart valve is warranted. A simplified approach including
pulmonary valvectomy and bioprosthetic tricuspid valve replacement surgery are the
procedures of choice. While surgical valve replacement is currently the gold
standard treatment for symptomatic carcinoid valve disease, transcatheter pulmonary
valve replacement should be considered as an alternative approach in high-risk
candidates<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>.
Percutaneous valve implantation in the pulmonary and in the inferior vena cava
positions may offer a novel, minimally invasive option avoiding open-heart surgery
in the high-risk patients<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. The
Medtronic Melody<sup>&#x000ae;</sup> valve and the Edwards
SAPIEN<sup>&#x000ae;</sup> valve are in use today for percutaneous pulmonary
valve implantation (PPVI) in children and in adults with congenital heart
disease<sup>[<xref rid="r24" ref-type="bibr">24</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>. Surgical complications can include bleeding,
carcinoid crises, right ventricular dysfunction, cardiac conduction disorders, renal
failure and sepsis<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p></sec><sec><title>DEBATES</title><p>Contrary to conventional guidelines of heart valve operation and choices of heart
valve prosthesis<sup>[<xref rid="r26" ref-type="bibr">26</xref>,<xref rid="r27" ref-type="bibr">27</xref>]</sup>, most surgeons prefer
bioprostheses in the tricuspid position because of the lower propensity to
thrombosis in carcinoid heart disease. However, questions have been raised about the
long-term durability of porcine valves exposed to the metabolic products of
carcinoid tumors. Progression onto a pulmonary valve homograft and onto a tricuspid
bioprosthetic valve has been reported<sup>[<xref rid="r28" ref-type="bibr">28</xref>,<xref rid="r29" ref-type="bibr">29</xref>]</sup>. While most
surgeons would prefer to use a bioprosthetic valve for replacement of the tricuspid
valve, many reports of the surgical treatment of carcinoid heart disease describe
the use of mechanical valves, because of the concern about secondary development of
carcinoid lesions in bioprostheses. An antibiotic sterilized aortic homograft can be
a candidate prosthesis for pulmonary valve replacement<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. In addition, pulmonary valvotomy or valvectomy, as
opposed to pulmonary valve replacement, remains controversial<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Patients who have no
contraindication for valve surgery and whose cardiac symptoms develop at an early
stage of the disease should undergo operation. The comparisons of the valve
prosthesis of choice are shown in <xref ref-type="table" rid="t3">Table
3</xref>.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Advantages and disadvantages of valvular prostheses of choices for carcinoid
heart disease patients<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r28" ref-type="bibr">28</xref>]</sup>.</p></caption><table frame="hsides" rules="cols"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr style="border-bottom-width:thin;border-bottom-style:solid"><th align="left" rowspan="1" colspan="1">Valvular Prosthesis</th><th align="left" rowspan="1" colspan="1">Advantage</th><th align="center" rowspan="1" colspan="1">Disadvantage</th></tr></thead><tbody><tr style="border-bottom-width:thin;border-bottom-style:solid"><td align="left" rowspan="1" colspan="1">Mechanical</td><td align="left" rowspan="1" colspan="1">No carcinoid involvement.</td><td align="left" rowspan="1" colspan="1">Long-term coagulation therapy</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Better short-term outcomes</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Valve durability</td><td align="left" rowspan="1" colspan="1">Carcinoid plaque deposition</td></tr><tr><td align="left" rowspan="1" colspan="1">Bioprosthesis</td><td align="left" rowspan="1" colspan="1">Uncommon carcinoid involvement</td><td align="left" rowspan="1" colspan="1">Prosthetic degeneration</td></tr><tr style="border-bottom-width:thin;border-bottom-style:solid"><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Avoidance of long-term warfarin use &#x00026; secondary
coagulopathies</td><td align="left" valign="top" rowspan="1" colspan="1">Organizing thrombus</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Short durability</td></tr><tr><td align="left" rowspan="1" colspan="1">Bioprosthesis (stentless)</td><td align="left" rowspan="1" colspan="1">No need of long-term coagulation therapy</td><td align="left" rowspan="1" colspan="1">Potential of restenosis</td></tr><tr style="border-bottom-width:thin;border-bottom-style:solid"><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Higher incidence of reintervention</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Homograft constriction</td></tr><tr><td align="left" rowspan="1" colspan="1">Homograft</td><td align="left" rowspan="1" colspan="1">No need of long-term coagulation therapy</td><td align="left" rowspan="1" colspan="1">Homograft calcification Plaque deposition</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Premature dysfunction with accelerated stenosis</td></tr></tbody></table></table-wrap></sec><sec><title>OUTCOMES</title><p>Severity of tricuspid valve regurgitation was an important predictor of
outcome<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>In these patients with advanced metastatic carcinoid disease, prognosis was poor,
with a median survival of only 2.6 years after diagnosis of cardiac involvement. The
severity and hemodynamic consequence of carcinoid heart disease contributes to the
high mortality<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Analysis of 17
series with carcinoid heart disease patients who had undergone surgical biological
tricuspid valve replacement revealed a 30-day mortality of 20%. It was suggested
that biological valves have an acceptable lifespan in carcinoid heart
disease<sup>[<xref rid="r30" ref-type="bibr">30</xref>,<xref rid="r31" ref-type="bibr">31</xref>]</sup>. Long-standing severe pulmonary valve
regurgitation, as seen after pulmonary valvectomy, may have a detrimental effect on
right ventricular remodeling<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>.
Schoen et al.<sup>[<xref rid="r32" ref-type="bibr">32</xref>]</sup> reported a case
of carcinoid heart disease, in which they observed carcinoid plaque that involved
the tricuspid bioprosthesis at postmortem examination. The 3-year mortality for
patients with carcinoid heart disease showed a 31% survival rate, significantly
lower than that of patients without cardiac involvement<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Conradi et al.<sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup> reported transcatheter pulmonary valve
replacement resulted in a favorable acute outcome in both of their patients, with
adequate valve function and good heart function. The patients tolerated the
procedure well without any complications. The perioperative mortality rate was
reduced from &#x0003e;20% to currently &#x0003c;10%<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. The overall operative mortality was 10%<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. The survival between the cardiac
and noncardiac groups was not statistically different (survival from onset of
symptoms: 13.6 years <italic>vs.</italic> 9.7 years; survival from time of
diagnosis: 4.8 years <italic>vs.</italic> 7 years)<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Carcinoid heart disease is a rare cause of right-side heart valve disease.
Echocardiography remains a reliable method for the definite diagnosis. Valve
replacement is currently the gold standard treatment for symptomatic carcinoid valve
disease. However, debates remain in terms of the choice of heart valve prosthesis.
The surgical management of the pulmonary valve relies on the pathological extent and
patient's condition. Transcatheter pulmonary valve replacement should be considered
as an alternative approach in high-risk candidates.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1">Authors&#x02019; roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">SMY</td><td align="left" rowspan="1" colspan="1">Study conception and design; analysis and/or
interpretation <break/>of data; manuscript writing; final approval
of the manuscript</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at The First Hospital of Putian, Teaching Hospital,
Fujian Medical University, Putian, Fujian Province, People's Republic of
China.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellikka</surname><given-names>PA</given-names></name><name><surname>Tajik</surname><given-names>AJ</given-names></name><name><surname>Khandheria</surname><given-names>BK</given-names></name><name><surname>Seward</surname><given-names>JB</given-names></name><name><surname>Callahan</surname><given-names>JA</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Carcinoid heart disease. Clinical and echocardiographic spectrum
in 74 patients</article-title><source>Circulation</source><year>1993</year><volume>87</volume><issue>4</issue><fpage>1188</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">7681733</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>DJ</given-names></name><name><surname>Khattar</surname><given-names>RS</given-names></name></person-group><article-title>Carcinoid heart disease: presentation, diagnosis, and
management</article-title><source>Heart</source><year>2004</year><volume>90</volume><issue>10</issue><fpage>1224</fpage><lpage>1228</lpage><pub-id pub-id-type="pmid">15367531</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>MS</given-names></name><name><surname>Manners</surname><given-names>JM</given-names></name></person-group><article-title>Valve replacement in carcinoid syndrome. Anaesthetic management
for tricuspid and pulmonary valve surgery</article-title><source>Anaesthesia</source><year>1979</year><volume>34</volume><issue>5</issue><fpage>494</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">474951</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Materazzo</surname><given-names>C</given-names></name><name><surname>Meazza</surname><given-names>R</given-names></name><name><surname>Stefanelli</surname><given-names>M</given-names></name><name><surname>Biasi</surname><given-names>S</given-names></name></person-group><article-title>Left valvular involvement in carcinoid: description of a
case</article-title><source>G Ital Cardiol</source><year>1994</year><volume>24</volume><issue>4</issue><fpage>429</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">8056218</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le M&#x000e9;tayer</surname><given-names>P</given-names></name><name><surname>Constans</surname><given-names>J</given-names></name><name><surname>Bernard</surname><given-names>N</given-names></name><name><surname>Roudaut</surname><given-names>R</given-names></name><name><surname>Pellegrin</surname><given-names>JL</given-names></name><name><surname>Lacoste</surname><given-names>D</given-names></name><etal/></person-group><article-title>Carcinoid heart disease: two cases of left heart involvement
diagnosed by transthoracic and transoesophageal
echocardiography</article-title><source>Eur Heart J</source><year>1993</year><volume>14</volume><issue>12</issue><fpage>1721</fpage><lpage>1723</lpage><pub-id pub-id-type="pmid">8131775</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>RR</given-names></name><name><surname>Castillo</surname><given-names>JG</given-names></name></person-group><article-title>Carcinoid heart disease: the challenge of the unknown
known</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>66</volume><issue>20</issue><fpage>2197</fpage><lpage>2200</lpage><pub-id pub-id-type="pmid">26564597</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>JG</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name><name><surname>Fischer</surname><given-names>GW</given-names></name></person-group><article-title>Absence of the tricuspid valve due to severe carcinoid heart
disease</article-title><source>Rev Esp Cardiol</source><year>2010</year><volume>63</volume><issue>1</issue><fpage>96</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">20089230</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robiolio</surname><given-names>PA</given-names></name><name><surname>Rigolin</surname><given-names>VH</given-names></name><name><surname>Wilson</surname><given-names>JS</given-names></name><name><surname>Harrison</surname><given-names>JK</given-names></name><name><surname>Sanders</surname><given-names>LL</given-names></name><name><surname>Bashore</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Carcinoid heart disease. Correlation of high serotonin levels
with valvular abnormalities detected by cardiac catheterization and
echocardiography</article-title><source>Circulation</source><year>1995</year><volume>92</volume><issue>4</issue><fpage>790</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">7641358</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luis</surname><given-names>SA</given-names></name><name><surname>Pellikka</surname><given-names>PA</given-names></name></person-group><article-title>Carcinoid heart disease: diagnosis and management</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2016</year><volume>30</volume><issue>1</issue><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">26971851</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000f8;ller</surname><given-names>JE</given-names></name><name><surname>Connolly</surname><given-names>HM</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name><name><surname>Seward</surname><given-names>JB</given-names></name><name><surname>Modesto</surname><given-names>K</given-names></name><name><surname>Pellikka</surname><given-names>PA</given-names></name></person-group><article-title>Factors associated with progression of carcinoid heart
disease</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><issue>11</issue><fpage>1005</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">12637610</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basson</surname><given-names>MD</given-names></name><name><surname>Ahlman</surname><given-names>H</given-names></name><name><surname>Wangberg</surname><given-names>B</given-names></name><name><surname>Modlin</surname><given-names>IM</given-names></name></person-group><article-title>Biology and management of the midgut carcinoid</article-title><source>Am J Surg</source><year>1993</year><volume>165</volume><issue>2</issue><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">8427415</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuetenhorst</surname><given-names>JM</given-names></name><name><surname>Bonfrer</surname><given-names>JM</given-names></name><name><surname>Korse</surname><given-names>CM</given-names></name><name><surname>Bakker</surname><given-names>R</given-names></name><name><surname>van Tinteren</surname><given-names>H</given-names></name><name><surname>Taal</surname><given-names>BG</given-names></name></person-group><article-title>Carcinoid heart disease: the role of urinary
5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic
peptide, transforming growth factor-beta and fibroblast growth
factor</article-title><source>Cancer</source><year>2003</year><volume>97</volume><issue>7</issue><fpage>1609</fpage><lpage>1615</lpage><pub-id pub-id-type="pmid">12655516</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuetenhorst</surname><given-names>JM</given-names></name><name><surname>Korse</surname><given-names>CM</given-names></name><name><surname>Bonfrer</surname><given-names>JM</given-names></name><name><surname>Bakker</surname><given-names>RH</given-names></name><name><surname>Taal</surname><given-names>BG</given-names></name></person-group><article-title>Role of natriuretic peptides in the diagnosis and treatment of
patients with carcinoid heart disease</article-title><source>Br J Cancer</source><year>2004</year><volume>90</volume><issue>11</issue><fpage>2073</fpage><lpage>2079</lpage><pub-id pub-id-type="pmid">15150565</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>JG</given-names></name><name><surname>Silvay</surname><given-names>G</given-names></name><name><surname>Sol&#x000ed;s</surname><given-names>J</given-names></name></person-group><article-title>Current concepts in diagnosis and perioperative management of
carcinoid heart disease</article-title><source>Semin Cardiothorac Vasc Anesth</source><year>2013</year><volume>17</volume><issue>3</issue><fpage>212</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">23171718</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>HM</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name><name><surname>Abel</surname><given-names>MD</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name><name><surname>Askew</surname><given-names>JW</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Early and late outcomes of surgical treatment in carcinoid heart
disease</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>66</volume><issue>20</issue><fpage>2189</fpage><lpage>2196</lpage><pub-id pub-id-type="pmid">26564596</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>HM</given-names></name></person-group><source>Carcinoid heart disease</source><date-in-citation content-type="access-date">Apr 5 2014</date-in-citation><comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com/contents/carcinoid-heart-disease">http://www.uptodate.com/contents/carcinoid-heart-disease</ext-link></comment></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voigt</surname><given-names>PG</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Teng</surname><given-names>OY</given-names></name><name><surname>Koolbergen</surname><given-names>DR</given-names></name><name><surname>Holman</surname><given-names>E</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Double bioprosthetic valve replacement in right-sided carcinoid
heart disease</article-title><source>Ann Thorac Surg</source><year>2005</year><volume>79</volume><issue>6</issue><fpage>2147</fpage><lpage>2149</lpage><pub-id pub-id-type="pmid">15919333</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidecker</surname><given-names>B</given-names></name><name><surname>Moore</surname><given-names>P</given-names></name><name><surname>Bergsland</surname><given-names>EK</given-names></name><name><surname>Merrick</surname><given-names>SH</given-names></name><name><surname>Rao</surname><given-names>RK</given-names></name></person-group><article-title>Transcatheter pulmonic valve replacement in carcinoid heart
disease</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2015</year><volume>16</volume><issue>9</issue><fpage>1046</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">26003151</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narine</surname><given-names>KK</given-names></name><name><surname>Dohmen</surname><given-names>PM</given-names></name><name><surname>Daenen</surname><given-names>W</given-names></name></person-group><article-title>Tricuspid and pulmonary valve involvement in carcinoid
disease</article-title><source>Tex Heart Inst J</source><year>2000</year><volume>27</volume><issue>4</issue><fpage>405</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">11198317</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aroesty</surname><given-names>JM</given-names></name><name><surname>DeWeese</surname><given-names>JA</given-names></name><name><surname>Hoffman</surname><given-names>MJ</given-names></name><name><surname>Yu</surname><given-names>PN</given-names></name></person-group><article-title>Carcinoid heart disease. Successful repair of the valvular
lesions under cardiopulmonary bypass</article-title><source>Circulation</source><year>1966</year><volume>34</volume><issue>1</issue><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">5328533</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpena</surname><given-names>C</given-names></name><name><surname>Kay</surname><given-names>JH</given-names></name><name><surname>Mendez</surname><given-names>AM</given-names></name><name><surname>Redington</surname><given-names>JV</given-names></name><name><surname>Zubiate</surname><given-names>P</given-names></name><name><surname>Zucker</surname><given-names>R</given-names></name></person-group><article-title>Carcinoid heart disease. Surgery for tricuspid and pulmonary
valve lesions</article-title><source>Am J Cardiol</source><year>1973</year><volume>32</volume><issue>2</issue><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">4721119</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuire</surname><given-names>MR</given-names></name><name><surname>Pugh</surname><given-names>DM</given-names></name><name><surname>Dunn</surname><given-names>MI</given-names></name></person-group><article-title>Carcinoid heart disease. Restrictive cardiomyopathy as a late
complication</article-title><source>J Kans Med Soc</source><year>1978</year><volume>79</volume><issue>12</issue><fpage>661</fpage><lpage>665</lpage><page-range>661-2, 665</page-range><pub-id pub-id-type="pmid">722145</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laule</surname><given-names>M</given-names></name><name><surname>Pschowski</surname><given-names>R</given-names></name><name><surname>Pape</surname><given-names>UF</given-names></name><name><surname>Pavel</surname><given-names>M</given-names></name><name><surname>Stangl</surname><given-names>V</given-names></name><name><surname>Baumann</surname><given-names>G</given-names></name><etal/></person-group><article-title>Staged catheter-based valve treatment of severe carcinoid heart
disease</article-title><source>Neuroendocrinology</source><year>2015</year><volume>103</volume><issue>3-4</issue><fpage>259</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">26138598</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lurz</surname><given-names>P</given-names></name><name><surname>Bonhoeffer</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>AM</given-names></name></person-group><article-title>Percutaneous pulmonary valve implantation: an
update</article-title><source>Expert Rev Cardiovasc Ther</source><year>2009</year><volume>7</volume><issue>7</issue><fpage>823</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">19589118</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalal</surname><given-names>Z</given-names></name><name><surname>Thambo</surname><given-names>JB</given-names></name><name><surname>Boudjemline</surname><given-names>Y</given-names></name></person-group><article-title>The future of transcatheter pulmonary valvulation</article-title><source>Arch Cardiovasc Dis</source><year>2014</year><volume>107</volume><issue>11</issue><fpage>635</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">25241221</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feguri</surname><given-names>GR</given-names></name><name><surname>Macruz</surname><given-names>H</given-names></name><name><surname>Bulh&#x000f5;es</surname><given-names>D</given-names></name><name><surname>Neves</surname><given-names>A</given-names></name><name><surname>Castro</surname><given-names>RM</given-names></name><name><surname>Fonseca</surname><given-names>L</given-names></name><etal/></person-group><article-title>Aortic valve replacement with different types of prosthesis: are
there differences in the outcomes during hospital phase?</article-title><source>Rev Bras Cir Cardiovasc</source><year>2008</year><volume>23</volume><issue>4</issue><fpage>534</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">19229427</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ten&#x000f3;rio</surname><given-names>EM</given-names></name><name><surname>Moraes Neto</surname><given-names>F</given-names></name><name><surname>Chauvaud</surname><given-names>S</given-names></name><name><surname>Moraes</surname><given-names>CR</given-names></name></person-group><article-title>Experience with the posterior leaflet extension technique for
correction of rheumatic mitral insufficiency in children</article-title><source>Rev Bras Cir Cardiovasc</source><year>2009</year><volume>24</volume><issue>4</issue><fpage>567</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">20305931</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohri</surname><given-names>SK</given-names></name><name><surname>Schofield</surname><given-names>JB</given-names></name><name><surname>Hodgson</surname><given-names>H</given-names></name><name><surname>Oakley</surname><given-names>CM</given-names></name><name><surname>Keogh</surname><given-names>BE</given-names></name></person-group><article-title>Carcinoid heart disease: early failure of an allograft valve
replacement</article-title><source>Ann Thorac Surg</source><year>1994</year><volume>58</volume><issue>4</issue><fpage>1161</fpage><lpage>1163</lpage><pub-id pub-id-type="pmid">7944771</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Chertow</surname><given-names>GM</given-names></name><name><surname>Karlson</surname><given-names>EW</given-names></name><name><surname>Neish</surname><given-names>AS</given-names></name><name><surname>Schoen</surname><given-names>FJ</given-names></name></person-group><article-title>Bioprosthetic tricuspid valve stenosis associated with extensive
plaque deposition in carcinoid heart disease</article-title><source>Am Heart J</source><year>1991</year><volume>121</volume><issue>6</issue><issue-part>Pt 1</issue-part><fpage>1835</fpage><lpage>1838</lpage><pub-id pub-id-type="pmid">2035407</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>A</given-names></name><name><surname>Sill</surname><given-names>B</given-names></name><name><surname>Schoenebeck</surname><given-names>J</given-names></name><name><surname>Schneeberger</surname><given-names>Y</given-names></name><name><surname>Reichenspurner</surname><given-names>H</given-names></name><name><surname>Gulbins</surname><given-names>H</given-names></name></person-group><article-title>Failing stentless bioprostheses in patients with carcinoid heart
valve disease</article-title><source>J Cardiothorac Surg</source><year>2015</year><volume>10</volume><fpage>41</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1186/s13019-015-0238-5.</pub-id><pub-id pub-id-type="pmid">25880286</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabvuure</surname><given-names>N</given-names></name><name><surname>Cumberworth</surname><given-names>A</given-names></name><name><surname>Hindocha</surname><given-names>S</given-names></name></person-group><article-title>In patients with carcinoid syndrome undergoing valve replacement:
will a biological valve have acceptable durability?</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2012</year><volume>15</volume><issue>3</issue><fpage>467</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">22691379</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoen</surname><given-names>FJ</given-names></name><name><surname>Hausner</surname><given-names>RJ</given-names></name><name><surname>Howell</surname><given-names>JF</given-names></name><name><surname>Beazley</surname><given-names>HL</given-names></name><name><surname>Titus</surname><given-names>JL</given-names></name></person-group><article-title>Porcine heterograft valve replacement in carcinoid heart
disease</article-title><source>J Thorac Cardiovasc Surg</source><year>1981</year><volume>81</volume><issue>1</issue><fpage>100</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">7453210</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conradi</surname><given-names>L</given-names></name><name><surname>Schaefer</surname><given-names>A</given-names></name><name><surname>Mueller</surname><given-names>GC</given-names></name><name><surname>Seiffert</surname><given-names>M</given-names></name><name><surname>Gulbins</surname><given-names>H</given-names></name><name><surname>Blankenberg</surname><given-names>S</given-names></name><etal/></person-group><article-title>Carcinoid heart valve disease: transcatheter pulmonary
valvein-valve implantation in failing biological xenografts</article-title><source>J Heart Valve Dis</source><year>2015</year><volume>24</volume><issue>1</issue><fpage>110</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">26182628</pub-id></element-citation></ref></ref-list></back></article>